A detailed history of Silverarc Capital Management, LLC transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Silverarc Capital Management, LLC holds 3,687,548 shares of PSTX stock, worth $34.8 Million. This represents 2.62% of its overall portfolio holdings.

Number of Shares
3,687,548
Previous 3,607,999 2.2%
Holding current value
$34.8 Million
Previous $10.5 Million 0.1%
% of portfolio
2.62%
Previous 2.99%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.7 - $4.04 $214,782 - $321,377
79,549 Added 2.2%
3,687,548 $10.5 Million
Q2 2024

Aug 14, 2024

BUY
$2.0 - $3.46 $23,046 - $39,869
11,523 Added 0.32%
3,607,999 $10.5 Million
Q1 2024

May 14, 2024

SELL
$2.76 - $4.13 $301,676 - $451,421
-109,303 Reduced 2.95%
3,596,476 $11.5 Million
Q4 2023

Feb 14, 2024

BUY
$1.83 - $3.51 $252,163 - $483,656
137,794 Added 3.86%
3,705,779 $12.5 Million
Q3 2023

Nov 13, 2023

BUY
$1.62 - $2.79 $1.01 Million - $1.74 Million
622,037 Added 21.12%
3,567,985 $8.49 Million
Q2 2023

Aug 14, 2023

BUY
$1.66 - $3.4 $426,034 - $872,599
256,647 Added 9.54%
2,945,948 $5.18 Million
Q1 2023

May 15, 2023

BUY
$3.08 - $8.73 $1.41 Million - $4.01 Million
459,301 Added 20.6%
2,689,301 $8.28 Million
Q4 2022

Feb 14, 2023

SELL
$3.33 - $6.38 $1.08 Million - $2.07 Million
-324,277 Reduced 12.7%
2,230,000 $11.8 Million
Q3 2022

Oct 28, 2022

BUY
$2.43 - $4.51 $5.28 Million - $9.8 Million
2,173,671 Added 571.11%
2,554,277 $9.02 Million
Q2 2022

Jul 25, 2022

BUY
$1.87 - $5.0 $263,501 - $704,550
140,910 Added 58.79%
380,606 $982,000
Q1 2022

May 13, 2022

BUY
$3.22 - $7.04 $15,340 - $33,538
4,764 Added 2.03%
239,696 $1.07 Million
Q4 2021

Feb 14, 2022

BUY
$6.23 - $7.6 $1.46 Million - $1.79 Million
234,932 New
234,932 $1.6 Million

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $811M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.